Acurion, Inc. — SEC Form D Filing

Acurion, Inc. filed an SEC Form D on April 15, 2026, reporting $4.14M raised in Health Technology.

Form D filing details

Filing
SEC Form D
Filing date
April 15, 2026
Amount reported
$4.14M
Round stage
Seed
Industry
Health Technology
Website
https://acurionhealth.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Many cancer patients do not receive approved precision oncology therapies in time due to delays in testing.

Solution

Acurion's OncoGaze™ technology provides genomic insights quickly, enabling oncologists to offer precision therapies sooner.

Why now

The increasing number of FDA-approved precision oncology therapies highlights the need for faster testing and treatment delivery.

Verdict

Investors were drawn to Acurion because the urgency of delivering precision oncology therapies faster resonated in the context of the expanding market for such treatments, not because they had clear evidence of significant differentiation from incumbents. The implicit bet was that the demand for quick genomic insights would sustain Acurion's growth trajectory. However, the limited upside lies in the competitive landscape, where established players may easily overshadow new entrants unless Acurion demonstrates a distinct technological edge.

Source: SEC EDGAR Form D filing